NKTX

Nkarta Inc

1.79

Oct 23 • 3:59 PM ET +0.05 (2.87%)

1.79

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: ARTV FATE CABA KYTX RNAC IPSC ALLO CRBU CLLS SANA

| Held by: VTI IWM VXF IWN VTWO DFAS IWC BUSM PRFZ AVSC

Scroll to Statements

Index	RUT
Market Cap	128.20M
Enterprise Value	18.98M
Income	-117.32M
Sales	0.00M
Book/sh	3.46
Cash/sh	2.55
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	108
IPO	Jul 10, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.52
P/C	0.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.98
Current Ratio	7.98
Debt/Eq	0.30
LT Debt/Eq	0.27
Option/Short	Yes / Yes

EPS (ttm)	-1.58
EPS next Y	-1.52
EPS next Q	-0.40
EPS this Y	-18.32%
EPS next Y	9.09%
EPS next 5Y	1.82%
EPS past 3/5Y	18.61% 23.69%
Sales past 3/5Y	- -
EPS Y/Y TTM	-6.70%
Sales Y/Y TTM	-
EPS Q/Q	-74.47%
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	-49.88% -

Insider Own	19.62%
Insider Trans	-0.01%
Inst Own	64.19%
Inst Trans	2.54%
ROA	-29.86%
ROE	-38.76%
ROIC	-37.36%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-17.56%
SMA50	-28.94%
SMA200	-29.65%
Trades

Shs Outstand	71.62M
Shs Float	57.57M
Short Float	6.36%
Short Ratio	5.31
Short Interest	3.66M
52W High	3.72 -51.88%
52W Low	1.70 5.29%
Volatility	5.82% 5.98%
ATR (14)	0.14
RSI (14)	24.66
Beta	1.21
Rel Volume	1.39
Avg Volume	689.94K
Volume	959,160

Perf Week	-0.56%
Perf Month	-37.19%
Perf Quarter	-20.80%
Perf Half Y	-38.70%
Perf YTD	-3.24%
Perf Year	-20.80%
Perf 3Y	-2.45%
Perf 5Y	-89.54%
Perf 10Y	-
Recom	1.00
Target Price	10.83
Prev Close	1.74
Price	1.79
Change %	2.87%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-23-26	Initiated	TD Cowen	Buy
May-15-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$14
Aug-14-24	Upgrade	Raymond James	Outperform → Strong Buy	$16
Mar-22-24	Downgrade	Raymond James	Strong Buy → Outperform	$13 → $16
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Oct-10-22	Initiated	Canaccord Genuity	Buy	$25
Jul-28-22	Initiated	Needham	Buy	$26
Jul-18-22	Initiated	SVB Leerink	Outperform	$30
Mar-11-22	Initiated	Raymond James	Outperform	$17
Mar-08-22	Initiated	H.C. Wainwright	Buy	$25
Jan-06-22	Initiated	William Blair	Outperform
Nov-18-21	Initiated	SMBC Nikko	Outperform	$50
Jul-16-21	Initiated	Oppenheimer	Outperform	$75
Aug-04-20	Initiated	Stifel	Buy	$41
Aug-04-20	Initiated	Mizuho	Buy	$34
Aug-04-20	Initiated	Evercore ISI	Outperform	$55
Aug-04-20	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-10-26 07:00AM	Nkarta to Participate in September Investor Conferences (GlobeNewswire)
Sep-08-26 07:00AM	Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 (GlobeNewswire) +10.62%
Aug-10-26 04:24PM	Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) -5.28%
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
Jun-26-26 08:45AM	Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference (GlobeNewswire)
09:00AM	Loading…
May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire)
May-19-26 09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire)
May-12-26 04:01PM	Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) -6.71%
Apr-15-26 04:01PM	Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers (GlobeNewswire) +5.68% +15.70%
Apr-09-26 07:00AM	Nkarta to Participate in Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-26 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Feb-27-26 08:00AM	Nkarta to Participate in March Investor Conferences (GlobeNewswire)
Dec-02-25 07:09AM	Nkarta to Participate in Evercore Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-30-25 01:14PM	Nkarta to Participate in November Investor Conferences (GlobeNewswire)
10:07AM	Loading…
Oct-22-25 10:07AM	Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting (GlobeNewswire) -7.95%
Sep-02-25 08:01AM	Nkarta to Participate in a September Investor Conference (GlobeNewswire)
Aug-12-25 04:01PM	Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +12.76%
Jul-23-25 08:01AM	Nkarta to Participate in the H.C. Wainwright "HCW@Home" Series (GlobeNewswire) +7.21%
Jun-06-25 08:52AM	Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus (GlobeNewswire)
May-19-25 12:00PM	Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade (Zacks)
May-15-25 03:46PM	Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space (Benzinga) -8.02%
May-14-25 04:01PM	Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire)
Apr-14-25 12:00PM	Nkarta (NKTX) Upgraded to Buy: Here's Why (Zacks) +7.94%
Apr-01-25 08:01AM	Nkarta to Participate in an April Investor Conference (GlobeNewswire)
Mar-31-25 10:41AM	Nkarta: Grinding Lower, Trying To Find Support (Seeking Alpha) -8.00%
10:15AM	Nkarta: Betting On The Turnaround (Seeking Alpha)
Mar-27-25 06:55AM	Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy (BioPharma Dive) +43.80%
Mar-26-25 04:01PM	Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-20-25 09:35AM	Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
09:35AM	Loading…
Mar-19-25 09:35AM	Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-25-25 08:01AM	Nkarta to Participate in March Investor Conferences (GlobeNewswire)
Dec-05-24 06:01AM	Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2 (GlobeNewswire)
Nov-26-24 07:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire)
Nov-22-24 06:50AM	Nkarta price target lowered to $16 from $20 at Mizuho (TipRanks)
Nov-12-24 08:02AM	Nkarta to Participate in an Upcoming Investor Conference (GlobeNewswire) -10.03%
Nov-07-24 04:02PM	Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Oct-09-24 08:00AM	Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month (Benzinga)
Sep-03-24 04:01PM	Nkarta to Participate in Upcoming Investor Conference (GlobeNewswire)
Aug-14-24 12:37PM	Why Nkarta Stock Is Soaring Today (Motley Fool)
Aug-13-24 09:03PM	Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-24-24 06:00AM	Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus (GlobeNewswire)
Jul-16-24 06:01AM	Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President (GlobeNewswire) +13.96%
Jul-10-24 12:00PM	Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know (Zacks)
Jul-01-24 10:20AM	3 Undervalued Stocks Primed for a 2X Return (InvestorPlace)
Jun-27-24 06:00AM	Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications (GlobeNewswire)
Jun-13-24 04:01PM	Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors (GlobeNewswire)
May-10-24 02:56PM	Nkarta Inc (NKTX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Analysis (GuruFocus.com)
May-09-24 10:57PM	NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-07-24 06:30AM	Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's Radar (InvestorPlace)
Apr-03-24 04:02PM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-24 04:06PM	Why Nkarta Stock Just Boomeranged Following A Massive Dive On Friday (Investor's Business Daily) +17.60% -5.91%
06:30AM	Nkarta Announces Pricing of $240 Million Underwritten Offering (GlobeNewswire)
Mar-23-24 05:31AM	Nkarta Inc (NKTX) Posts Full Year 2023 Financial Results: A Focus on NKX019 and Pipeline Realignment (GuruFocus.com)
Mar-22-24 04:03PM	Why Top 1% Biotech Stock Nkarta Just Plummeted, Undercutting Its 50-Day Line (Investor's Business Daily) -31.28% +17.60%
09:18AM	Nkarta's blood cancer CAR stalls again, with falling response rate forcing it out of the race (FierceBiotech.com)
Mar-21-24 10:54PM	NKTX Stock Earnings: Nkarta Beats EPS for Q4 2023 (InvestorPlace)
04:01PM	Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-19-24 07:29AM	3 Overlooked Stocks Ready to Capture the Market by Storm (InvestorPlace) +7.19%
Feb-29-24 06:30AM	3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket (InvestorPlace) +11.13%
Feb-28-24 08:01AM	Nkarta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-20-24 04:19PM	Last Call! 7 Small-Cap Stocks Ready to Explode in Value (InvestorPlace) -7.66%
Feb-08-24 09:32AM	3 Under-the-Radar Stocks Set to Soar 300% by 2026 (InvestorPlace) +7.87%
Feb-06-24 12:50PM	3 Sleeper Stocks With Serious Potential to Make You a Millionaire (InvestorPlace) +11.95%
Feb-05-24 12:41PM	3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential (InvestorPlace) -5.59%
Feb-04-24 08:00AM	Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge (InvestorPlace)
Jan-09-24 10:25AM	Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 (GlobeNewswire)
Dec-09-23 08:31PM	Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition (GlobeNewswire)
Dec-08-23 12:00PM	All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy (Zacks)
Nov-14-23 03:56PM	T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta Inc (GuruFocus.com) +20.42%
Nov-09-23 04:02PM	Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
11:38AM	These Biotech Stocks Could Double Your Money, According To Analysts (Benzinga)
Nov-07-23 08:02AM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire)
Oct-25-23 02:06PM	Want To Invest In Penny Stocks? Here Are Three That Analysts Think Could Deliver Over 300% Returns (Benzinga)
Oct-18-23 10:47AM	Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug (Zacks)
01:18AM	'The world increasingly needs Arm,' says KeyBanc: 4 big analyst picks (Investing.com)
Oct-17-23 08:17PM	Nkarta stock soars 112% after FDA clears cell therapy to go beyond cancer into lupus (FierceBiotech.com) +112.16%
11:47AM	Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis (PR Newswire)
07:01AM	Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis (GlobeNewswire)
Oct-16-23 04:01PM	Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures (GlobeNewswire)
Oct-02-23 03:07PM	3 Promising Biotech Stocks That Will Make Early Investors Rich (InvestorPlace) -5.76%
Aug-10-23 07:01AM	Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Aug-03-23 08:02AM	Nkarta to Participate at Upcoming Investor Conference (GlobeNewswire)
Jul-31-23 06:30PM	3 Hidden Penny Stocks That Could Turn $100 into $10,000 (InvestorPlace) +6.51%
Jul-05-23 04:02PM	Nkarta Appoints Alyssa Levin Chief Financial and Business Officer (GlobeNewswire) -6.87%
Jun-28-23 09:35AM	Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks (Zacks) -11.74%
Jun-27-23 01:02PM	Why Shares of Nkarta Are Slumping Tuesday (Motley Fool) -37.97%
07:01AM	Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire)
Jun-26-23 04:01PM	Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +12.24%
Jun-10-23 10:47AM	Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-11-23 04:02PM	Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
04:01PM	Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma (GlobeNewswire)
May-09-23 07:15AM	We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely (Simply Wall St.)
May-07-23 12:50PM	7 Stocks With Promising Upside Potential for 100% Returns (InvestorPlace)
Apr-17-23 05:01PM	Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 09:06PM	Nkarta to Participate at Upcoming Investor Conferences (GlobeNewswire) +14.06%
Apr-11-23 09:46AM	3 Biotech Stocks to Watch for Potential Breakthroughs (InvestorPlace)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HASTINGS PAUL J	Chief Executive Officer	Jun 18 '26	Sale	2.71	1,776	4,813	390,247	Jun 22 04:05 PM
HASTINGS PAUL J	Chief Executive Officer	Jan 15 '26	Sale	2.07	26,046	53,915	390,023	Jan 20 05:39 PM
Mahmood Nadir	President	Jan 15 '26	Sale	2.07	5,649	11,693	167,727	Jan 20 05:38 PM

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

CEO & DirectorMr. Paul J. Hastings

President and Principal Accounting & Financial OfficerDr. Nadir Mahmood Ph.D.

Ph.D.Dr. Shawn Rose M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTX

Nkarta Inc

Upgrade your Finviz experience